论文部分内容阅读
目的 探讨治疗急性脑梗死有效的方案。 方法 观察发病在 4 8h内的急性脑梗死患者 78例 ,随机分为蕲蛇酶配以高压氧治疗组 (高压氧组 )和蕲蛇酶治疗组 (蕲蛇酶组 )。 结果 治疗前后两组总有效率分别为 94 .7%和 92 .5%。基本治愈、显著进步百分比是高压氧组高于蕲蛇酶组 ,但差异不显著 (P >0 .0 5)。神经功能缺损程度总分数治疗前后比较 ,蕲蛇酶配以高压氧组第 1个疗程后 ,差异显著 (P <0 .0 5) ,第 2个疗程后 ,差异极显著 (P <0 .0 1 ) ;蕲蛇酶组第 1个疗程及第 2个疗程后 ,差异均不明显 (P <0 .0 5)。 结论 蕲蛇酶配以高压氧组优于蕲蛇酶组
Objective To investigate the effective treatment of acute cerebral infarction. Methods 78 patients with acute cerebral infarction within 48 hours were randomly divided into acutobin plus hyperbaric oxygen group (HBO group) and viper group (viper group). Results The total effective rates of the two groups before and after treatment were 94.7% and 92.5% respectively. Basically cured, the percentage of significant progress was higher in hyperbaric oxygen group than in viper group, but the difference was not significant (P> 0.05). The total score of neurological deficit before and after treatment compared with the first treatment with hyperhidrosis after the first time, the difference was significant (P <0. 05), the second course of treatment, the difference was significant (P <0 .0 1). There was no significant difference between the first and the second courses of viper group (P <0.05). Conclusion Acanthopanax enzyme with hyperbaric oxygen group is superior to viper group